RT Journal Article
SR Electronic
T1 SARS-CoV-2 risk taxation model and validation based on large scale Dutch test-events
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.10.21268254
DO 10.1101/2022.01.10.21268254
A1 Bas Kolen
A1 Laurens Znidarsic
A1 Andreas Voss
A1 Simon Donders
A1 Iris Kamphorst
A1 Maarten van Rijn
A1 Dimitri Bonthuis
A1 Merit Cloquet
A1 Maarten Schram
A1 Rutger Scharloo
A1 Tim Boersma
A1 Tim Stobernack
A1 Pieter van Gelder
YR 2022
UL http://medrxiv.org/content/early/2022/01/10/2022.01.10.21268254.abstract
AB In response to the outbreak of SARS-CoV-2 many governments decided in 2020 to impose lockdowns. Although the package of measures which constitute such lockdowns differs between countries, it is a general rule that contacts between people, and especially in large groups of people, are avoided or prohibited. The main reasoning behind these measures is preventing that healthcare systems become overloaded. As of 2021 vaccines against SARS-CoV-2 are available, but these do not guarantee 100% risk reduction and it will take a while for the world to reach a sufficient immune status. This raises the question whether and under which conditions events like theater shows, conferences, professional sports events, concerts and festivals can be organized. The current paper presents a COVID-19 Risk taxation method for (large scale) events. This method can be applied to events to define an alternative package of measures replacing generic social distancing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Click NL, see https://www.clicknl.nl/en/about-clicknl/Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Ethics Committee TU Delft (http://hrec.tudelft.nl/) The application is approved by the Ethics Committee on the 4 December 2020. Contact persons: Ir. J.B.J. Groot Kormelink, secretary HREC Dr. Ir. U. Pesch Chair HREC Faculty of Technology, Policy and Management.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript